Search Results

PCI for the Left Main Coronary Artery

With the availability of drug-eluting stents (DES) and the dramatic reduction in restenosis rates they have provided, the results of left main coronary artery (LMCA) stenting have certainly improved compared to preliminary experiences with bare-metal stents (BMS), which were limited by high restenosis rates and sudden deaths.1-6 Encouraging results have been reported at midterm clinical follow-up in some observational registries with elective DES implantation in the LMCA, with a 1-year mortality rate of 0% to 5%.7-12 In these registries, the need for target lesion revascularization (TLR) varied from 0% to 14%, and target vessel revascularization (TVR) varied from 0% to 19%.

Single-Center Study Supports CTCA for Routine Pre-TAVR Imaging

August 10, 2015—Alaide Chieffo, MD, et al published findings on the benefit of routine screening of coronary artery disease (CAD) with computed tomographic coronary angiography (CTCA) instead of invasive coronary angiography (CA) in patients undergoing transcatheter aortic valve replacement (TAVR) in a single-center investigation.

The Milan Experience Publishes 5-Year PCI Data

June 25, 2010—In the Journal of the American College of Cardiology: Cardiovascular Interventions, Alaide Chieffo, MD, et al reported the Milan Experience study's 5-year outcomes of percutaneous coronary interventions (PCI) with drug-eluting stent (DES) implantation versus coronary artery bypass grafting for unprotected left main coronary artery lesions (2010:3:595–601).

European Study Compares Medtronic and Edwards TAVI Devices

January 16, 2013—Results from the PRAGMATIC Plus Initiative (Pooled-Rotterdam-Milano-Toulouse In Collaboration) were published online ahead of print by Alaide Chieffo, MD, et al in the Journal of the American College of Cardiology.

TAVR Outcomes for Women Evaluated Using WIN-TAVI Registry

January 2, 2018—Findings from the first WIN-TAVI (Women’s International Transcatheter Aortic Valve Implantation) registry evaluating 1-year clinical outcomes of transcatheter aortic valve replacement (TAVR) in women were reported by Alaide Chieffo, MD, et al online in Journal of the American College of Cardiology (JACC): Cardiovascular Interventions.

SCAI and WIN Launch Women's Health Initiative

January 27, 2010—The Society for Cardiovascular Angiography and Interventions (SCAI) announced the launch of "WINHeart—Score a WIN for Women," an initiative to raise awareness surrounding gender-based disparities in the diagnosis, treatment, and survival of women with cardiovascular disease (CVD).

SCAI and WIN Launch Women’s Health Initiative and Report on Gender Disparity in CVD Treatment

January 27, 2010—The Society for Cardiovascular Angiography and Interventions (SCAI) announced the launch of "WINHeart—Score a WIN for Women," an initiative to raise awareness surrounding gender-based disparities in the diagnosis, treatment, and survival of women with cardiovascular disease (CVD).

Medinol's EluNIR DES Receives CE Mark Approval

October 26, 2017—Medinol USA announced that it has obtained European CE Mark approval for its EluNIR ridaforolimus-eluting coronary stent system, which features a low metal footprint and the company's elastomeric coating.